Myasthenia Gravis News is providing virtual coverage of the Myasthenia Gravis Foundation of America’s scientific session at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting taking place Oct. 29 in San Francisco. Stay tuned to this page for all the latest news.
A single dose of KYV-101, a cell therapy being developed by Kyverna Therapeutics for generalized myasthenia gravis (gMG), led to rapid and sustained reductions in symptom severity — lasting up to…
Read moreA single dose of KYV-101, a cell therapy being developed by Kyverna Therapeutics for generalized myasthenia gravis (gMG), led to rapid and sustained reductions in symptom severity — lasting up to…
Nearly one year of treatment with Remegen’s telitacicept in a clinical trial in China led to substantial and sustained reductions in symptom severity among adults with generalized myasthenia gravis (gMG). That’s according…
Treatment with Imaavy (nipocalimab-aahu) has led to sustained disease control for up to 1.5 years among adolescents with generalized myasthenia gravis (gMG), according to data from the long-term extension (LTE) part of…
Weekly treatment with gefurulimab —an investigational C5 inhibitor from Alexion, Astrazeneca Rare Disease, that’s designed to be self-administered — led to early and sustained reductions in disease severity for adults with…
Vyvgart (efgartigimod alfa-fcab) led to significant and clinically meaningful reductions in disease severity among adults with generalized myasthenia gravis (gMG) who test negative for disease-causing antibodies targeting the acetylcholine receptor (AChR). Notably,…
Vyvgart (efgartigimod alfa-fcab), currently approved in the U.S. for treating certain adults with generalized myasthenia gravis (gMG), safely eased disease severity in adolescents with the disease, according to new data from a…
Get regular updates to your inbox.
